Marketdash
Back to News

Wall Street Analysts See Major Upside for Accenture and 9 Other Stocks This Tuesday

MarketDash Editorial Team
8 hours ago
Leading Wall Street analysts issued fresh ratings and price targets on Tuesday, with Accenture seeing a potential 16% rally ahead. Morgan Stanley upgraded the consulting giant while firms reshuffled their outlooks across tech, healthcare, and real estate sectors.

Wall Street's top analysts shuffled theirdecks on Tuesday, issuing fresh ratings and price targets across a diverse set of stocks. The headline mover? Accenture Plc (ACN), which caught an upgrade that suggests there's serious upside ahead.

The Big Upgrade: Accenture Gets a Fresh Look

Morgan Stanley analyst James Faucette upgraded Accenture (ACN) from Equal-Weight to Overweight, raising the price target from $271 to $320. That's a meaningful jump considering the stock closed at $274.66 on Monday. Do the math and you're looking at potential upside of more than 16%. Apparently, Morgan Stanley sees something they like in the consulting giant's prospects.

Biotech and Healthcare Making Waves

The healthcare and biotech sectors saw plenty of action. Wedbush analyst Robert Driscoll increased the price target for Tyra Biosciences Inc (TYRA) from $30 to $37, maintaining an Outperform rating. The stock closed at $22.12 on Monday, so there's considerable runway if Driscoll's thesis plays out.

Chardan Capital went even bigger on Palvella Therapeutics Inc (PVLA), raising the price target from $110 to $174. Analyst Geulah Livshits maintained a Buy rating. With shares closing at $88.98 on Monday, that target suggests nearly double the upside.

SI-Bone Inc (SIBN) also got some love from Needham, which raised its price target from $24 to $27. Analyst David Saxon maintained a Buy rating on the medical device company. Shares closed at $18.41 on Monday.

Baird analyst Jeff Johnson upgraded Tandem Diabetes Care Inc (TNDM) from Neutral to Outperform, simultaneously boosting the price target from $18 to $30. The stock closed at $22.11 on Monday, putting it nicely between the old and new targets.

Over at Abivax SA (ABVX), Citizens analyst Jason Butler increased the price target from $114 to $131 while maintaining a Market Outperform rating. Shares settled at $117.91 on Monday.

Tech Gets a Mixed Reception

The technology sector saw divergent moves. Cantor Fitzgerald analyst C.J. Muse upgraded Microchip Technology Inc (MCHP) from Neutral to Overweight, boosting the price target from $65 to $85. The semiconductor company's shares closed at $67.18 on Monday, suggesting Muse sees a significant rebound ahead.

Rockwell Automation Inc (ROK) caught a substantial price target increase from Goldman Sachs, which raised its forecast from $329 to $448. Analyst Joe Ritchie upgraded the stock from Sell to Neutral. Shares settled at $401.65 on Monday, meaning Goldman is now considerably less bearish on the industrial automation company.

The Downgrade Corner

Not everyone got good news. Baird cut its price target on Dentsply Sirona Inc (XRAY) from $14 to $12, with analyst Jeffrey Johnson maintaining a Neutral rating. The dental equipment manufacturer's shares closed at $11.40 on Monday, already below even the reduced target.

Real Estate Gets Some Respect

Jefferies analyst Linda Tsai upgraded Federal Realty Investment Trust (FRT) from Hold to Buy, boosting the price target from $101 to $115. The retail REIT's shares closed at $100.91 on Monday, suggesting Tsai sees the real estate investment trust finally breaking through after trading around its previous target.

These analyst calls represent a snapshot of Wall Street sentiment heading into Tuesday's trading session. Whether these price targets prove prescient or overly optimistic will depend on execution, market conditions, and the inevitable surprises that make markets interesting. For now, analysts are putting their reputations behind some sizable moves.

Back to News

Wall Street Analysts See Major Upside for Accenture and 9 Other Stocks This Tuesday

MarketDash Editorial Team
8 hours ago
Leading Wall Street analysts issued fresh ratings and price targets on Tuesday, with Accenture seeing a potential 16% rally ahead. Morgan Stanley upgraded the consulting giant while firms reshuffled their outlooks across tech, healthcare, and real estate sectors.

Wall Street's top analysts shuffled theirdecks on Tuesday, issuing fresh ratings and price targets across a diverse set of stocks. The headline mover? Accenture Plc (ACN), which caught an upgrade that suggests there's serious upside ahead.

The Big Upgrade: Accenture Gets a Fresh Look

Morgan Stanley analyst James Faucette upgraded Accenture (ACN) from Equal-Weight to Overweight, raising the price target from $271 to $320. That's a meaningful jump considering the stock closed at $274.66 on Monday. Do the math and you're looking at potential upside of more than 16%. Apparently, Morgan Stanley sees something they like in the consulting giant's prospects.

Biotech and Healthcare Making Waves

The healthcare and biotech sectors saw plenty of action. Wedbush analyst Robert Driscoll increased the price target for Tyra Biosciences Inc (TYRA) from $30 to $37, maintaining an Outperform rating. The stock closed at $22.12 on Monday, so there's considerable runway if Driscoll's thesis plays out.

Chardan Capital went even bigger on Palvella Therapeutics Inc (PVLA), raising the price target from $110 to $174. Analyst Geulah Livshits maintained a Buy rating. With shares closing at $88.98 on Monday, that target suggests nearly double the upside.

SI-Bone Inc (SIBN) also got some love from Needham, which raised its price target from $24 to $27. Analyst David Saxon maintained a Buy rating on the medical device company. Shares closed at $18.41 on Monday.

Baird analyst Jeff Johnson upgraded Tandem Diabetes Care Inc (TNDM) from Neutral to Outperform, simultaneously boosting the price target from $18 to $30. The stock closed at $22.11 on Monday, putting it nicely between the old and new targets.

Over at Abivax SA (ABVX), Citizens analyst Jason Butler increased the price target from $114 to $131 while maintaining a Market Outperform rating. Shares settled at $117.91 on Monday.

Tech Gets a Mixed Reception

The technology sector saw divergent moves. Cantor Fitzgerald analyst C.J. Muse upgraded Microchip Technology Inc (MCHP) from Neutral to Overweight, boosting the price target from $65 to $85. The semiconductor company's shares closed at $67.18 on Monday, suggesting Muse sees a significant rebound ahead.

Rockwell Automation Inc (ROK) caught a substantial price target increase from Goldman Sachs, which raised its forecast from $329 to $448. Analyst Joe Ritchie upgraded the stock from Sell to Neutral. Shares settled at $401.65 on Monday, meaning Goldman is now considerably less bearish on the industrial automation company.

The Downgrade Corner

Not everyone got good news. Baird cut its price target on Dentsply Sirona Inc (XRAY) from $14 to $12, with analyst Jeffrey Johnson maintaining a Neutral rating. The dental equipment manufacturer's shares closed at $11.40 on Monday, already below even the reduced target.

Real Estate Gets Some Respect

Jefferies analyst Linda Tsai upgraded Federal Realty Investment Trust (FRT) from Hold to Buy, boosting the price target from $101 to $115. The retail REIT's shares closed at $100.91 on Monday, suggesting Tsai sees the real estate investment trust finally breaking through after trading around its previous target.

These analyst calls represent a snapshot of Wall Street sentiment heading into Tuesday's trading session. Whether these price targets prove prescient or overly optimistic will depend on execution, market conditions, and the inevitable surprises that make markets interesting. For now, analysts are putting their reputations behind some sizable moves.